SOX17 Expression in Mesotheliomas and Benign Mesothelial Proliferations: Implications for Differential Diagnosis With Gynecologic Carcinomas.
Journal
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
ISSN: 1538-7151
Titre abrégé: Int J Gynecol Pathol
Pays: United States
ID NLM: 8214845
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
aheadofprint
Résumé
SOX17 has recently emerged as a novel immunohistochemical marker for cancers of endometrial and ovarian origin with improved specificity compared with the widely used Mullerian marker PAX8. However, evaluation of SOX17 in benign and malignant peritoneal mesothelial proliferations remains limited, and these may mimic gynecologic carcinomas, particularly on small biopsies. We evaluated SOX17 and PAX8 expression in 20 benign mesothelial lesions (5 adenomatoid tumors, 5 well-differentiated papillary mesothelial tumors, and 10 peritoneal inclusion cysts) and 16 epithelioid peritoneal mesotheliomas. The 17 female and 3 male patients with benign mesothelial lesions ranged from 20 to 80 yr (median: 56.5 yr), while the 9 females and 7 males with mesothelioma ranged from 47 to 85 yr (median: 57.5 yr). SOX17 was positive in 5 (25%) benign lesions (2 adenomatoid tumors, 3 peritoneal inclusion cysts) and 2 (13%) mesotheliomas, while PAX8 stained 8 (40%) benign lesions (1 adenomatoid tumor, 1 well-differentiated papillary mesothelial tumor, 6 peritoneal inclusion cysts), and 2 (13%) mesotheliomas. Results for the 2 stains showed incomplete concordance, with agreement in 15 (75%) benign proliferations and 14 (88%) mesotheliomas. Our findings suggest that SOX17 positivity alone is insufficient to confirm a diagnosis of gynecologic carcinoma over a mesothelial proliferation and pathologists should exercise caution when these entities are diagnostic considerations.
Identifiants
pubmed: 39479966
doi: 10.1097/PGP.0000000000001076
pii: 00004347-990000000-00204
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 by the International Society of Gynecological Pathologists.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011;35:816–826.
Lu S, Yakirevich E, Hart J, et al. PAX8 expression in breast cancer. Appl Immunohistochem Mol Morphol 2021;29:293–298.
Shaker N, Chen W, Sinclair W, et al. Identifying SOX17 as a sensitive and specific marker for ovarian and endometrial carcinomas. Mod Pathol 2023;36:100038.
Zhang X, Yao J, Niu N, et al. SOX17: a highly sensitive and specific immunomarker for ovarian and endometrial carcinomas. Mod Pathol 2023;36:100001.
Hancock KL, Clinton CM, Dinkelspiel HE, et al. A case of mesothelioma masquerading pre-operatively as ovarian cancer and brief review of the literature. Gynecol Oncol Rep 2016;17:26–28.
Kapoor S, Mehta S, Samanta S, et al. Misdiagnosis of peritoneal mesothelioma as ovarian carcinoma in a young female: “who is gatecrashing your masquerade party?” Indian J Gynecol Oncol 2022;21:16.
Mani H, Merino MJ. Mesothelial neoplasms presenting as, and mimicking, ovarian cancer. Int J Gynecol Pathol 2010;29:523–528.
Wick MR, Mills SE, Dehner LP, et al. Serous papillary carcinomas arising from the peritoneum and ovaries. A clinicopathologic and immunohistochemical comparison. Int J Gynecol Pathol 1989;8:179–188.
Chapel DB, Husain AN, Krausz T, et al. PAX8 expression in a subset of malignant peritoneal mesotheliomas and benign mesothelium has diagnostic implications in the differential diagnosis of ovarian serous carcinoma. Am J Surg Pathol 2017;41:1675–1682.
Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 2010;34:627–635.
Tandon RT, Jimenez-Cortez Y, Taub R, et al. Immunohistochemistry in peritoneal mesothelioma: a single-center experience of 244 cases. Arch Pathol Lab Med 2018;142:236–242.
Ordonez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol 2006;13:16–25.
Sun M, Zhao L, Weng Lao I, et al. Well-differentiated papillary mesothelioma: a 17-year single institution experience with a series of 75 cases. Ann Diagn Pathol 2019;38:43–50.
Xing D, Banet N, Sharma R, et al. Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study. Hum Pathol 2018;72:160–166.
Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 2002;3:167–170.
Sakamoto Y, Hara K, Kanai-Azuma M, et al. Redundant roles of Sox17 and Sox18 in early cardiovascular development of mouse embryos. Biochem Biophys Res Commun 2007;360:539–544.
He S, Kim I, Lim MS, et al. Sox17 expression confers self-renewal potential and fetal stem cell characteristics upon adult hematopoietic progenitors. Genes Dev 2011;25:1613–1627.
Satturwar S, Shaker N, Sinclair W, et al. SOX17 is a highly sensitive and specific marker for metastatic ovarian and endometrial carcinomas in cytology cell block specimens. Cancer Cytopathol 2023;131:465–470.
Bollinger DJ, Wick MR, Dehner LP, et al. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma. A histochemical and immunohistochemical comparison. Am J Surg Pathol 1989;13:659–670.
Clement PB, Young RH, Scully RE. Malignant mesotheliomas presenting as ovarian masses. A report of nine cases, including two primary ovarian mesotheliomas. Am J Surg Pathol 1996;20:1067–1080.
Malpica A, Euscher ED, Marques-Piubelli ML, et al. Localized malignant peritoneal mesothelioma (LMPeM) in women: a clinicopathologic study of 18 cases. Am J Surg Pathol 2022;46:1352–1363.
Beebe-Dimmer JL, Fryzek JP, Yee CL, et al. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol 2016;8:743–750.
Malpica A, Euscher ED, Marques-Piubelli ML, et al. Malignant mesothelioma of the peritoneum in women: a clinicopathologic study of 164 cases. Am J Surg Pathol 2021;45:45–58.
Kiyokawa T. Peritoneal pathology review: Mullerian, mucinous and mesothelial lesions. Surg Pathol Clin 2022;15:259–276.
Folkins AK, Longacre TA. Low-grade serous neoplasia of the female genital tract. Surg Pathol Clin 2019;12:481–513.
Malpica A, Sant’Ambrogio S, Deavers MT, et al. Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases. Am J Surg Pathol 2012;36:117–127.
Lerias S, Ariyasriwatana C, Agaimy A, et al. Adenomatoid tumor of the uterus: a report of 6 unusual cases with prominent cysts including 4 with diffuse myometrial involvement, 4 with uterine serosal involvement, and 2 presenting in curettage specimens. Int J Gynecol Pathol 2021;40:248–256.
Devins KM, Baranov E, Hung YP, et al. Large and extensive multilocular peritoneal inclusion cysts lack genomic alterations and follow an indolent clinical course despite rare recurrences. Am J Surg Pathol 2024;48:1177–1184.
Ordonez NG. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol 2013;26:553–562.
Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004;44:109–115.
Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002;117:541–545.
Zarychta E, Lepinay K, Szubert S, et al. Wilms’ tumor 1 antigen immunoreactivity in epithelial ovarian cancer - diagnostic and prognostic value. Folia Histochem Cytobiol 2020;58:198–207.
Comin CE, Saieva C, Messerini L. h-Caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007;31:1139–1148.
Nofech-Mozes S, Khalifa MA, Ismiil N, et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol 2008;21:1147–1155.
Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203–1214.
Barnetson RJ, Burnett RA, Downie I, et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 2006;125:67–76.
Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 2006;19:34–48.
Takeshima Y, Amatya VJ, Kushitani K, et al. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases. Am J Clin Pathol 2008;130:771–779.
Ordonez NG. Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma. Mod Pathol 2013;26:1132–1143.
Devins KM, Zukerberg L, Watkins JC, et al. BAP1 and Claudin-4, but not MTAP, reliably distinguish borderline and low-grade serous ovarian tumors from peritoneal mesothelioma. Int J Gynecol Pathol 2023;42:159–166.
Kawai T, Tominaga S, Hiroi S, et al. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses. J Clin Pathol 2016;69:706–712.